Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Cephalalgia · 2018 · 10.5K citations · Full text

Medicine, Neurology, Neurotology +6

Adherence to oral migraine-preventive medications among patients with chronic migraine

Zsolt Hepp, David W. Dodick, Sepideh F. Varon et al. · Cephalalgia · 2014 · 434 citations

Pharmacy, Pharmacotherapy, Clinical Pharmacology +13

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

Daniel Serrano, Richard B. Lipton, I Scher et al. · The Journal of Headache and Pain · 2017 · 227 citations · Full text

Public Health, Neurology, Individual Differences +16

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

Uwe Reuter, Marc Ehrlich, Astrid Gendolla et al. · Cephalalgia · 2021 · 178 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

Messoud Ashina, Peter J. Goadsby, Uwe Reuter et al. · European Journal of Neurology · 2021 · 178 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14